GSK lifted profit guidance for the year on Wednesday after sales of the drugmaker's 'specialty' medicines soared.

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

BAE Systems also came under pressure, falling 24p to 1797p despite its upgrade to 2025 guidance. GSK also surrendered initial ...

(Alliance News) - GSK predicted an annual outturn at the top end of guidance, BAE Systems maintained its outlook, while Aston Martin softened its profit forecast. Here is what you need to know before ...

The FTSE 100 enjoyed another leap towards record territory as the index pushed around 0.7 per cent higher on Tuesday, ...

Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 7.8% in the morning session after the ...

GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to ...

Shares of medical technology company Enovis Corporation (NYSE:ENOV) jumped 3.3% in the morning session after the stock gained ...

In May, biotech iTeos Therapeutics decided to close down after being abandoned by GSK over the disappointing mid-stage ...

Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products ...